论文部分内容阅读
目的探讨酚妥拉明、多巴酚丁胺、低分子肝素钙、托拉塞米联合治疗肺心病重度心力衰竭的临床疗效与安全性。方法将62例病人随机分为治疗组和对照组,各31例,两组均给予持续低流量吸氧、改善通气、抗炎、解痉平喘、止咳化痰、强心利尿、纠正水电失衡等综合治疗,治疗组在对照组的基础上,加用酚妥拉明、多巴酚丁胺、低分子肝素钙、托拉塞米联合治疗。结果治疗组总有效率93.55%明显优于对照组总有效率61.29%,具有显著差异(P<0.01)。结论在常规治疗上加用酚妥拉明、多巴酚丁胺、低分子肝素钙、托拉塞米治疗肺心病重度心力哀碣,疗效显著,也相对安全,值得推广应用。
Objective To investigate the clinical efficacy and safety of phentolamine, dobutamine, low molecular weight heparin and torsemide in the treatment of patients with severe heart failure with pulmonary heart disease. Methods Sixty-two patients were randomly divided into treatment group and control group, with 31 cases in each group. Both groups were given continuous low-flow oxygen, improved ventilation, anti-inflammatory, antispasmodic and asthma, cough and phlegm, cardiac diuretic, Treatment, treatment group in the control group based on the addition of phentolamine, dobutamine, low molecular weight heparin, torsemide combination therapy. Results The total effective rate 93.55% in the treatment group was significantly better than 61.29% in the control group, with significant difference (P <0.01). Conclusions The conventional treatment of phentolamine, dobutamine, low molecular weight heparin, torasemide treatment of severe pulmonary heart disease mourning, significant effect, but also relatively safe, it is worth promoting the application.